AUS
NZ
UK
CA
USA
IND
Morgans senior analyst Scott Power initiated the Health Invest 2024 event, held in Sydney, with a comprehensive overview of the biotechnology and life sciences sectors to an audience that included both professional and retail investors. Power highlighted the robust performance of the biotech/life sciences sector both locally and globally, noting, “The life sciences sector has seen a solid calendar 2024 so far,” with the Bioshares Index rising 8% in the first half and $1.2 billion raised, exceeding the total amount raised in 2023.
Despite this positive momentum, Power pointed out that there remains significant room for growth within the local sector, emphasizing that “only a third of the companies across the sector achieving share price gains” this year. He also discussed the U.S. market, which has risen 14% year-to-date, noting an uptick in IPO activity. “A cut in interest rates from the US Federal Reserve will likely see investor interest continue to grow in the life sciences sector both in the US and Australia,” Power stated.
Power further expressed optimism about the potential resurgence of interest in the sector, stating, “If we’re right with this US interest rate cut, we might see more interest coming back into the space, and there will be plenty of upside for the sector over the rest of the year.”
The event featured several Australian companies showcasing their innovations and strategies within this promising market environment.
Imricor Medical Systems (ASX:IMR)
Nick Corkhill, Vice President of Corporate Strategy at Imricor, discussed the company's focus on developing MRI-compatible devices for cardiac ablation. Corkhill highlighted the challenges associated with traditional X-ray guidance, stating that it exposes patients and physicians to radiation and lacks the capability to visualize soft tissue accurately. Imricor’s devices, proven safe and effective within an MRI magnetic field, represent a significant advancement in cardiac care. The company is currently conducting its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial in support of FDA approval, anticipated in 2025.
Race Oncology (ASX:RAC)
Race Oncology’s Executive Chair Peter Smith presented the company’s innovative approach to cancer treatment by reviving the old anticancer drug bisantrene. Originally developed in the 1970s but never launched due to formulation challenges, Race Oncology has successfully reformulated bisantrene, addressing its solubility issues. Smith emphasized the company's unique position in the oncology landscape, as it aims to bring this new formulation to clinical trials. Race is targeting unmet needs in various oncology indications, including low-intensity treatments for acute myeloid leukemia.
Percheron Therapeutics (ASX:PER)
James Garner, Managing Director and CEO of Percheron Therapeutics, introduced the company's focus on developing therapies for orphan diseases. Garner discussed their lead program, ATL1102, targeting Duchenne muscular dystrophy (DMD), a severe genetic disease affecting young boys. Percheron has completed recruitment for its Phase 2b study of ATL1102, with results expected in the latter half of the year. The company aims to address significant unmet medical needs in DMD, which has a substantial market potential due to the lack of effective treatments.
Clarity Pharmaceuticals (ASX:CU6)
Dr. Alan Taylor, Executive Chair of Clarity Pharmaceuticals, highlighted the company’s groundbreaking work in the radiopharmaceutical sector. Clarity has achieved over 360% growth year-to-date, primarily due to its innovative product SAR-bisPSMA, which utilizes copper isotopes for prostate cancer diagnosis and therapy. The company received FDA Fast Track Designation for its diagnostic tool, which will expedite its regulatory review process and enhance its potential market entry.
ImpediMed (ASX:IPD)
Dr. Parmjot Bains, CEO and Managing Director of ImpediMed, discussed the company’s digital health platform, SOZO, which non-invasively detects and monitors lymphoedema, particularly in breast cancer survivors. SOZO, the only FDA-cleared device of its kind, employs bio-impedance spectroscopy to assess fluid status accurately. The company is focused on expanding its market presence and enhancing its product offerings to address various health needs.
Overall, the Health Invest 2024 event underscored the resilience and innovation within the Australian biotech sector, showcasing how companies are positioned to thrive in a rapidly evolving market.
